key: cord-0740429-h2f28ktx
authors: Zhang, Yuquan; Li, Ziyue; Milon Essola, Julien; Ge, Kun; Dai, Xuyan; He, Huining; Xiao, Haihua; Weng, Yuhua; Huang, Yuanyu
title: Biosafety materials: ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system
date: 2022-03-14
journal: Biosaf Health
DOI: 10.1016/j.bsheal.2022.03.010
sha: 08e9dde2d1f5f065eed339748a7e9ecee33e31a7
doc_id: 740429
cord_uid: h2f28ktx

Despite multiple virus outbreaks over the past decade, including the devastating coronavirus disease 2019 (COVID-19) pandemic, the lack of accurate and timely diagnosis and treatment technologies has wreaked havoc on global biosecurity. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has the potential to address these critical needs for tackling infectious diseases to detect viral nucleic acids and inhibit viral replication. This review summarizes how the CRISPR/Cas system is being utilized for the treatment and diagnosis of infectious diseases with the help of biosafety materials and highlights the design principle and in vivo and in vitro efficacy of advanced biosafety materials used to deal with virus attacks.

Biosafety materials refer to materials used to prevent and control biosafety problems. With the global outbreak of the coronavirus disease 2019 (COVID- 19) , biosafety materials are garnering much attention [1] . The concept of biosafety refers to all security problems caused by biological risk factors, including viruses, bacteria, alien species invasion, and other events. Therefore, biosafety materials must have the ability to prevent and control biological threats [2] . These materials proved to be highly efficient in a biosafety crisis by preserving the human body and other species from harm by establishing a solid biosafety line of defense for organisms subject to a novel invasion and mediating a quick response in a short amount of time [1] . Knowing the large range of possibilities granted by biosafety materials, the biosafety materials industry is foreseen to rapidly catch up with the shortage of biosafety materials and lack of protective equipment, which will significantly strengthen and improve China's defense against biological threats. However, the frequent occurrence of natural disasters nowadays causes various novel viruses and microorganisms to slowly "wake up." These constitute unknown biological threats that are often the cause of biosafety incidents. Biosafety materials can be used not only as a core element in the diagnosis and treatment of diseases but also as an "umbrella" for other methods of diagnosis and treatment. For example, they can be used as a safe delivery vehicle for drugs/reagents [3, 4] , including chemical drugs, genetic drugs, and others. Therefore, biosafety materials have broad application prospects in the detection and treatment of diseases.

From 2019 until today, the world has directly faced the threat of a global pandemic [5, 6] . Since its first appearance, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has exhibited characteristics that made it extremely difficult to control. Among them are its rapid human-human transmission and the varying degrees of variations in the transmission process [7] . These characteristics made SARS-CoV-2 a common global nightmare that inflicted an immeasurable impact on the global economy and society [6, 8] . Such a severe situation compels the scientific community to develop detection techniques that have a range of effective parameters, such as efficiency, suitability, and low cost [9] . Furthermore, the technology must be adaptable to virus mutations, with a potential for redesign when necessary. In line with this need, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) technology, which can be used to identify viral genome sequences, shows great potential for immediate diagnostics and editable sequence-based antiviral therapies.

Both viral and nonviral vectors have been studied for the delivery of CRISPR/Cas systems.

However, owing to the problems of gene mutations, insertion mutations, and immunogenicity in virusmediated CRISPR/Cas delivery, nonviral vectors, particularly those based on biosafety materials, are urgently needed. Compared with viral vectors, biosafety material-based nonviral vectors have more advantages, such as large gene packaging capacity, safety, and targeted delivery [10] . Therefore, the limitation of the clinical application of the CRISPR/Cas genome-editing system can be solved by using biosafety materials.

This topical review highlights recent advances in the in vivo delivery of the CRISPR/Cas system using various biosafety materials, including lipids, polymers, peptides, inorganic materials, and extracellular vesicles. The various CRISPR/Cas detection systems are also discussed in detail.

Reverse transcription polymerase chain reaction is currently the most widely used standard detection method. However, this technique generally needs to be performed in well-equipped laboratories that meet biosafety standards and requires trained operators/personnel and specific experimental reagents and instruments. These requirements are not conducive for the timely detection and classification of suspected cases and efficient result analysis, which may result in biosafety problems. Combining the just-in-time detection features of the CRISPR/Cas system with biosafety materials enables on-site sampling and testing. Herein, we summarize the latest detection techniques and methods involved in the detection of pathogenic microorganisms and discuss the specific application of this technology to provide relevant references related to the latest technology that can be used as an alternative in areas where appropriate detection is hindered by the lack of well-equipped laboratories.

The application of biosafety materials in combination with the CRISPR/Cas system can greatly improve test portability and readability. Cas9 cleavage can be combined with nucleic acid amplification for detecting specific nucleic acid sequences, which can be used to genotype pathogens and distinguish single-nucleotide polymorphisms (SNPs) [10, 11] . Zika virus (ZIKV), spread by the bite of an infected Aedes aegypti mosquito, emerged in Southeast Asia and several Pacific islands before spreading throughout Latin America and the Caribbean (Fig.1 A) [12] . Globally, quantitative real-time polymerase chain reaction (qPCR) is the gold standard for detecting viral RNA [13] . However, qPCR requires well-equipped laboratories and trained technicians for sample preparation. In addition, the required reagents must be refrigerated and the equipment used is expensive and energy-intensive [14] . In contrast, some simple devices, such as lateral flow test devices that use antibodies to directly detect viral antigens, have low sensitivity and may exhibit the problems of crossreactivity with locally prevalent dengue viruses [15] .

Therefore, detection methods that can quickly and accurately distinguish ZIKV are urgently needed. Pardee et al. successfully used nucleic acid sequence-based amplification and Cas9 effector for ZIKV detection and genotyping, achieving remarkable results [12] . A single guide RNA (sgRNA) with a strain-specific proto-spacer adjacent motif sequence was designed to cover SNPs present only in the American ZIKV genome but not in the African ZIKV genome. In the presence of sgRNA, Cas9 could only lyse the amplified products of the American ZIKV genome ( Fig.1 B) . To increase the practicability of this system, primers for isothermal RNA amplification and a toehold switch-based RNA sensor were designed in silico. In less than a day, ZIKV sensors can be embedded in paper and freeze-dried with cell-free transcription and translation systems for field deployment as a stable diagnostic tool. Detection of the appropriate trigger RNA was indicated by a change in the color of the paper plate from yellow to purple in approximately 3 h. The whole process, which took less than 7 days from preparation to detection, can be used to effectively handle numerous detection needs created by outbreaks. Further, the storage time of >1 year and storage temperature of 20°C greatly reduced the transportation and storage costs, thereby satisfying the needs of low-cost testing ( Fig.1 C) .

The combination of the lateral flow test and CRISPR/Cas can compensate for the shortcomings of the lateral flow test and improve the detection accuracy [16] . In addition to communicable diseases, similar tests can be used for foodborne diseases. A lateral flow test strip combined with Cas9 nickasetriggered isothermal DNA amplification was previously used in food quality surveillance [17] . CRISPR/Cas9 can distinguish between American and African Zika virus types [12] . C) Workflow for rapid prototyping of paper-based biomolecular sensors for portable and low-cost diagnostics [12] , Copyright 2016 Elsevier.

Cas13a is an RNA-guided RNA enzyme with CRISPR RNA (crRNA)-guided single-stranded RNA (ssRNA) cleavage activity [18, 19] . In 2016, Cas13a was found to have target RNA triggering "side-chain cleavage" activity [20] . After further exploring this activity, Zhang et al. developed the first comprehensive and adaptable CRISPR/Cas13-based nucleic acid detection system called specific high-sensitivity enzymatic reporter unlocked (SHERLOCK) [21] . This method can achieve aM (10 -18 mol/L) sensitivity for DNA and RNA targets with single-base resolution and has also been used to detect SARS-CoV-2 and other viruses [5] .

The SHERLOCK-based nucleic acid detection system has a wide range of applications in the detection of infectious diseases that affect biosecurity. To protect human biosecurity, Cameron et al.

used the SHERLOCK platform to detect ZIKV and dengue virus at concentrations as low as 1 copy/µL [22] . This system distinguished four dengue virus serotypes and region-specific strains of ZIKV from the 2015-2016 pandemic, proving to be a sensitive, specific, and rapidly field-deployable diagnostic tool for infectious diseases worldwide [22] . Similarly, canine parvovirus type 2 (CPV-2) causes a canine disease with high mortality. Haroon et al. used the SHERLOCK molecular detection system for specific high-sensitivity enzyme reporter genes to assess the sensitivity of this system for detecting CPV-2 DNA [23] . The nanosystem can detect 100 aM CPV-2 DNA in 30 min, which is timeefficient, effortless, and does not involve the use of complex instruments.

Subsequently, SHERLOCKv2, an update of SHERLOCK, was developed. Compared with SHERLOCK, SHERLOCKv2 has 3.5-fold better sensitivity owing to the combination of Cas13a with Csm6 [24] . Csm6 is an auxiliary type III CRISPR-triggered nuclease capable of binding its reporting signal to Cas13a for signal enhancement [14] . A portable paper lateral flow test strip was prepared by combining the FAM biotin reporter gene with anti-FAM antibody and gold nanoparticles [24] .

The class II V-A Cas12 (formerly known as Cpf1) effectors have lateral (or trans-cutting) activity [25] [26] [27] . However, unlike the Cas13 effector, the Cas12a effector targets DNA and transects side-branch single-stranded DNA (ssDNA), activating the DNA enzyme activity of Cas12a while cleaving the targeted double-stranded DNA (dsDNA). Cas12a cleaves ssDNA in a nonspecific manner [27] . In 2017, the trans-cutting activity of Cas12a and its application in nucleic acid detection (1-h low-cost multipurpose highly efficient system or HOLMES) was first reported in China, and a patent for the same was granted [28] . HOLMES can be used to detect DNA/RNA viruses and distinguish between viral genotypes and human SNPs from cell lines or clinical samples within 1 h with aM sensitivity. Moreover, Doudna's team at the University of California developed another new Cas12a-based technique, called DNA endonuclease-targeted CRISPR trans reporter or DETECTR, that could detect Human Papilloma Virus (HPV)-16 infection with 100% accuracy [26] . Based on this system, Kean's team developed an engineered AsCas12a enzyme for the diagnostic analysis of SARS-CoV-2, which is sensitive to viral genome mutations and temperature [29] .

In response to the unprecedented need for rapid diagnostics in the COVID-19 pandemic, Park's team developed the first digital CRISPR/Cas-assisted assay, called digitizationenhanced CRISPR/Cas-assisted one-pot virus detection (deCOViD) [30] . More important than microliter volume analysis, deCOViD uses analytical digitization to increase RNA concentrations in the subnanoliter digital reaction wells and facilitates rapid amplification, resulting in faster detection times at lower target concentrations as well as higher signal transfer rates, wider dynamic range, and better sensitivity. HOLMESv2 can target both ssDNA and dsDNA. It is one of the simplest CRISPR/Cas biosensing systems available for DNA detection.

Lipid nanoparticles (LNPs) are one of the most effective nucleic acid delivery systems [32, 33] .

LNPs have been widely used in the delivery of nucleic acids, including DNA, siRNA, and mRNA, due to their excellent transfection ability and low toxicity [3] . The Cas9 mRNA targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene was first injected to achieve significant gene knockout. This blocked HBV infection and showed high editing performance and anti-HBV effect [35, 36] .

In a recent study, Gao et al. used cationic lipids to deliver Cas9 RNPs in which sgRNA was designed to target transmembrane channel gene family 1 (Tmc1) genes to treat autosomal dominant hearing loss in hair cells. Nanocomposites were directly injected into the cochlea of newborn Tmc1 Bth/+ mice. The results revealed that the auditory brainstem response threshold was lower and the auditory shock response level was better in the experimental group than in the control group [37] .

In addition to delivering RNPs, LNPs can deliver plasmids and mRNA. Commercial LTX lipids were used to deliver streptococcus pyogenes Cas9 (SpCas9)-sgRNAs plasmids and subsequently inactivate HBV by targeting multiple HBV domains in vitro [38] . LNPs and homology directed repair/sgRNA templates were loaded in AAVs. After treating Fah knockout mice with this combined delivery system for 30 days, the markers of liver injury were significantly reduced and the body weight was stable in the experimental group, indicating that CRISPR/Cas9-based gene therapy has great potential in the treatment of genetic liver diseases, such as metabolic liver disease and hemophilia [39] .

The excessive use of antibiotics plays a major role in the emergence and transmission of multidrug-resistant bacteria [40] . Using the CRISPR/Cas system to specifically target bacterial pathogens for gene editing reduces microbial growth levels. Cas9 proteins were covalently modified using cationic polymers and then mixed with targeted antibiotic-resistant sgRNA to form small nanocomplexes (Fig.3 A) . Studies have shown that polymer-derived nanocomposites can be successfully introduced into methicillin-resistant Staphylococcus aureus to effectively edit the bacterial genome, thereby decreasing the growth of this organism [41] . Additionally, insulin sensitivity and adipose inflammation of high-fat-diet-induced type 2 diabetes can be improved with Cas9 mRNA/gNLRP3 treatment [42] . CLAN can also be used to deliver plasmids for genome editing in vivo. Wang 

One of the characteristics of Alzheimer's disease is the accumulation of amyloid β peptides.

Considering that the formation of amyloid β peptides is regulated by beta-secretase (Bace1), targeting production of GDNF in mammalian cells (Fig.4) . The secreted GDNF maintained its biological activity and promoted the sudden growth of the meridian, which was twice as long as that in the untreated group [47] . They complexed Cas9 RNP with EP peptide to form a nanocomplex (CriPs). CriPs disrupted the nuclear co-repressor of catabolism, nuclear receptor-interacting protein 1, and enhanced adipocytes browning , suggesting a promising treatment for metabolic diseases [48] .

Conditional responsive gene editing has shown advantages in disease treatment in recent years.

Ju et al. developed pH-dependent self-assembling gold nanoclusters (AuNCs). The assembly of gold nanoclusters (AuNCs) and SpCas9 proteins mainly depended on the pH value. SpCas9-AuNCs exhibited better affinity for higher pH values, evidenced by their ability to be highly stable at relatively high pH values. Further, SpCas9-AuNCs were unstable at lower pH values and appeared dismantled in most cases (Fig.5 A) . SpCas9-AuNCs effectively knocked out the oncogene E6 after the transfection of HPV18 E6 sgRNA, thereby restoring the function of the tumor suppressor protein p53 and inducing cell apoptosis [49] . and mouse models of Duchenne muscular dystrophy [53] .

Extracellular vesicles, including exosomes and microvesicles, are biological nanovesicles containing proteins, lipids, and nucleic acids that act as natural delivery vehicles [54] [55] [56] . They are released by most cells into the extracellular space and culture media and play an important role in intercellular signaling [57] . "Gesicle" is a microvesicle produced by the overexpression of vesicular stomatitis virus G glycoprotein and has been designed as a delivery vehicle for Cas9 RNP [58] [60] .

The development of biosafety materials is still in its infancy [1] . There are many challenges yet to be addressed and solved. From the perspective of applications in detection technologies, the great demand for virus detection technologies has compelled the scientific community to develop several low-cost biosafety materials. This is certainly a very challenging task, but it can substantially benefit the world, particularly the developing regions, where transmission and outbreaks of infectious diseases are more common due to poor healthcare facilities. In addition to infectious diseases, the technology can also be used in daily life to detect routine pathogenic microorganisms, maintain social and economy stability. An example is the food industry, which is expected to use microorganism detection techniques to maintain food safety.

Nowadays, viral vectors, such as adenoviral vectors and AAVs, are commonly used for gene editing. However, these viral vectors are often used to deliver Cas9 and sgRNA plasmid DNA, which have limits in the delivery of Cas proteins. Compared with plasmids, Cas9 RNPs have substantial advantages in terms of higher safety and fewer off-target effects and do not cause harm to normal tissues and organs. Therefore, it is necessary to design biosafety materials using materials that not only have the ability to carry plasmid DNA, mRNA, and Cas RNPs but also do not produce immune responses. The application of biosafety materials in CRISPR/Cas systems is in the initial stage. Most applications are related to cancer treatment. There are relatively few reports on the application of biosafety materials in infectious disease therapy and diagnosis.

Gene-editing tools work at the genetic level, presenting the biggest challenge for CRISPR/Cas systems. Until now, most CRISPR/Cas research has been conducted at the cellular and test-tube levels.

However, the ultimate goal of this technology is to achieve gene editing in living organisms, which is necessary to solve the specific problem . CRISPR/Cas systems may produce serious off-target effects.

Pattanayak et al. proved that the off-target efficiencywas up to 84% [61] . Recently, researchers have

conducted several studies to reduce the off-target effects of CRISPR/Cas systems [62, 63] . Several excellent reviews focusing on this topic have also been published [64] [65] [66] . The direct delivery of Cas9 protein and sgRNA into cells is more efficient than plasmid delivery because it eliminates the Cas9 expression step and reduces off-target cleavage. The large molecular weight of RNPs requires an appropriate delivery vector to properly carry the protein, posing challenges for the accurate design and application of biosafety materials.

Despite the rapid advances in CRISPR/Cas technology over the past decade, viral vectors remain the dominant delivery vehicles. Several nonviral vectors have emerged, including lipids, polymers, peptides, inorganic materials, and extracellular vesicles. The safety of materials has always been a concern for these carriers. As foreign substances, these materials will be recognized as antigens under certain conditions, leading to phagocytosis and clearance by immune cells, resulting in immune effects.

This poses new requirements for material innovation. These materials can be endowed with various properties to evade immune recognition. They can be modified with targeted groups and ligands for immune evasion to improve specificity and immune escape [67] . For example, CD47 provides the "Don't eat me" signal. Additionally, gene editing can be initiated by internal/external conditions, such as local microenvironmental changes and suitable light stimulation. For extracellular vesicles, which are natural carriers, a reliable way to obtain stable quality between batches is yet to be established.

Among the various delivery vehicles, lipids are most widely used in CRISPR/Cas systems owing to their safety and convenience. Biosafety materials should be able to be used in the detection and treatment of diseases and exhibit good biosafety characteristics. Therefore, biosafety materials should be reasonably designed for use in the delivery of the CRISPR/Cas system gene-editing tool to enable CRISPR/Cas system to enhance ability of accurate gene regulation to step forward in clinical research and application. 

Biosafety materials: an emerging new research direction of materials science from the COVID-19 outbreak

Developing biosafety materials science and building the national security wall of China

Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment

Biomaterials and nanomedicine for bone regeneration: Progress and future prospects

Detection of SARS-CoV-2 with sherlock one-pot testing

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a systemic infection

A vaccineinduced public antibody protects against SARS-CoV-2 and emerging variants

Cellular host factors for SARS-CoV-2 infection

Tools and techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 detection

Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics

CRISPR-Cas9 technology: applications and human disease modelling, Briefings Funct

Rapid, low-cost detection of Zika virus using programmable biomolecular components

What Ebola tells us about outbreak diagnostic readiness

Accelerated RNA detection using tandem CRISPR nucleases

Engineering paper-based sensors for Zika virus

Clustered regularly interspaced short palindromic repeats/Cas9-mediated lateral flow nucleic acid assay

A lateral flow strip combined with Cas9 nickase-triggered amplification reaction for dual food-borne pathogen detection

Advances in clustered, regularly interspaced short palindromic repeats (CRISPR)-based diagnostic assays assisted by micro/nanotechnologies

Detect and destroy: CRISPR-based technologies for the response against viruses

Functional features and current applications of the RNA-targeting type VI CRISPR-Cas systems

SHERLOCK: nucleic acid detection with CRISPR nucleases

Field-deployable viral diagnostics using CRISPR-Cas13

CRISPR-Cas13a mediated nanosystem for attomolar detection of canine parvovirus type 2

Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6

Point-of-care devices to detect Zika and other emerging viruses

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity

CRISPR-based diagnostics

CRISPR-Cas12a-assisted nucleic acid detection

An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and rapid COVID-19 testing

Digital CRISPR/Cas-assisted assay for rapid and sensitive detection of SARS-CoV-2

HOLMESv2: a CRISPR-Cas12b-assisted patform for nucleic acid detection and DNA methylation quantitation

The challenge and prospect of mRNA therapeutics landscape

RNAi therapeutic and its innovative biotechnological evolution

Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition

An orthogonal array optimization of Lipid-like nanoparticles for mRNA delivery in vivo

A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus

Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo

Something old, something new: revisiting natural products in antibiotic drug discovery

Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases

Nanoparticles based on poly (βamino ester) and HPV16-targeting CRISPR/shRNA as potential srugs for HPV16-related cervical malignancy

Optimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammation

In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease

Engineered amphiphilic peptides enable delivery of proteins and CRISPRassociated nucleases to airway epithelia

Localized delivery of CRISPR/dCas9 via layer-by-layer self-assembling peptide coating on nanofibers for neural tissue engineering

CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (Nrip1) in adipose cells to enhance energy expenditure

Gold nanocluster-mediated efficient delivery of Cas9 protein through pH-induced assembly-disassembly for inactivation of virus oncogenes

Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection

Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases

Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations

Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair

The challenges and possibilities of extracellular vesicles as therapeutic vehicles

Exosomes as targeted delivery platform of CRISPR/Cas9 for therapeutic genome editing

Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells

Macrophage-derived extracellular vesicle promotes hair growth

Protein transfer into human cells by VSV-G-induced nanovesicles

Gesiclemediated delivery of CRISPR/Cas9 ribonucleoprotein complex for inactivating the HIV provirus

Exosome-mediated CRISPR/Cas9 system targets to cut the intercellular transmission function of hepatitis B virus genome, Chin

High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity

CRISPR-Net: A recurrent convolutional network quantifies CRISPR off-target activities with mismatches and indels

Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito

CRISPR system: discovery, development and off-target detection

CRISPR/Cas systems in genome editing: methodologies and tools for sgrna design, off-target evaluation, and strategies to mitigate off-target effects

Latest developed strategies to minimize the offtarget effects in CRISPR-Cas-mediated genome editing

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

The authors declare that there are no conflicts of interest.